Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro

International Immunopharmacology

Volumn 8, Issue 5, 2008, Pages 679-687

  Grattendick, K J ^a   Nakashima, J M ^a   Feng, L ^a   Giri, S N ^a   Margolin, S B ^a  

^a Solanan Inc   (United States)

Author keywords

Cytokines; Etanercept; Infliximab; Pirfenidone; Tumor necrosis factor alpha

Indexed keywords

ETANERCEPT; INFLIXIMAB; LIPOPOLYSACCHARIDE; PIRFENIDONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; BIOASSAY; CELL SECRETION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL SURVIVAL; CULTURE MEDIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; PYRIDONES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41149162536     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.01.013     Document Type: Article

References (54)

1. Black R.A., Rauch C.T., Kozlosky C.J., Peschon J.J., Slack J.L., Wolfson M.F., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
2. Decoster E., Vanhaesebroeck B., Vandenabeele P., Grooten J., and Fiers W. Generation and biological characterization of membrane-bound, uncleavable murine tumor necrosis factor. J Biol Chem 270 (1995) 18473-18478
3. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
4. Grell M., Wajant H., Zimmermann G., and Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 95 (1998) 570-575
5. Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., and Boldin M.P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17 (1999) 331-367
6. Old L.J. Tumor necrosis factor (TNF). Science 230 (1985) 630-632
7. Vandenabeele P., Declercq W., Beyaert R., and Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 5 (1995) 392-399
8. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10 (1992) 411-452
9. Caron G., Delneste Y., Aubry J.P., Magistrelli G., Herbault N., Blaecke A., et al. Human NK cells constitutively express membrane TNF-alpha (mTNFalpha) and present mTNFalpha-dependent cytotoxic activity. Eur J Immunol 29 (1999) 3588-3595
10. Decker T., Lohmann-Matthes M.L., and Gifford G.E. Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 138 (1987) 957-962
11. Higuchi M., Nagasawa K., Horiuchi T., Oike M., Ito Y., Yasukawa M., et al. Membrane tumor necrosis factor-alpha (TNF-alpha) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation-characterization of membrane TNF-alpha. Clin Immunol Immunopathol 82 (1997) 133-140
12. Watts A.D., Hunt N.H., Wanigasekara Y., Bloomfield G., Wallach D., Roufogalis B.D., et al. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. Embo J 18 (1999) 2119-2126
13. Ferran C., Dautry F., Merite S., Sheehan K., Schreiber R., Grau G., et al. Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest 93 (1994) 2189-2196
14. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., and Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168 (2002) 5342-5351
15. 4+ T cells. J Immunol 166 (2001) 130-136
16. Eissner G., Kirchner S., Lindner H., Kolch W., Janosch P., Grell M., et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 164 (2000) 6193-6198
17. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 (2000) 1586-1593
18. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
19. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
20. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
21. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
22. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346 (2002) 1349-1356
23. Munoz-Fernandez S., Hidalgo V., Fernandez-Melon J., Schlincker A., and Martin-Mola E. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 358 (2001) 1644
24. Bowen J.D., Maravilla K., and Margolin S.B. Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. Mult Scler 9 (2003) 280-283
25. Walker J.E., Giri S.N., and Margolin S.B. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult Scler 11 (2005) 149-158
26. Walker J.E., and Margolin S.B. Pirfenidone for chronic progressive multiple sclerosis. Mult Scler 7 (2001) 305-312
27. Nakazato H., Oku H., Yamane S., Tsuruta Y., and Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 446 (2002) 177-185
28. Oku H., Nakazato H., Horikawa T., Tsuruta Y., and Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 446 (2002) 167-176
29. Cain W.C., Stuart R.W., Lefkowitz D.L., Starnes J.D., Margolin S., and Lefkowitz S.S. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 20 (1998) 685-695
30. Hale M.L., Margolin S.B., Krakauer T., Roy C.J., and Stiles B.G. Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun 70 (2002) 2989-2994
31. Akassoglou K., Bauer J., Kassiotis G., Lassmann H., Kollias G., and Probert L. Transgenic models of TNF induced demyelination. Adv Exp Med Biol 468 (1999) 245-259
32. Hofman F.M., Hinton D.R., Johnson K., and Merrill J.E. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170 (1989) 607-612
33. Merrill J.E., and Benveniste E.N. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci 19 (1996) 331-338
34. van Oosten B.W., Barkhof F., Scholten P.E., von Blomberg B.M., Ader H.J., and Polman C.H. Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis. Arch Neurol 55 (1998) 793-798
35. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
36. Sicotte N.L., and Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57 (2001) 1885-1888
37. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., and Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26 (1980) 171-176
38. Morgan C.D., Mills K.C., Lefkowitz D.L., and Lefkowitz S.S. An improved colorimetric assay for tumor necrosis factor using WEHI 164 cells cultured on novel microtiter plates. J Immunol Methods 145 (1991) 259-262
39. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.Y., Shealy D., et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301 (2002) 418-426
40. Clark I.A. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 18 (2007) 335-343
41. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151 (1993) 1548-1561
42. Solorzano C.C., Ksontini R., Pruitt J.H., Hess P.J., Edwards P.D., Kaibara A., et al. Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor. J Immunol 158 (1997) 414-419
43. Xin L., Wang J., Zhang H., Shi W., Yu M., Li Q., et al. Dual regulation of soluble tumor necrosis factor-alpha induced activation of human monocytic cells via modulating transmembrane TNF-alpha-mediated 'reverse signaling'. Int J Mol Med 18 (2006) 885-892
44. Filion L.G., Graziani-Bowering G., Matusevicius D., and Freedman M.S. Monocyte-derived cytokines in multiple sclerosis. Clin Exp Immunol 131 (2003) 324-334
45. Kappos L., Moeri D., Radue E.W., Schoetzau A., Schweikert K., Barkhof F., et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353 (1999) 964-969
46. Aderka D., Engelmann H., Maor Y., Brakebusch C., and Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175 (1992) 323-329
47. Giri S.N., Wang Q., Xie Y., Lango J., Morin D., Margolin S.B., et al. Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. Biopharm Drug Dispos 23 (2002) 203-211
48. Giri S.N., Leonard S., Shi X., Margolin S.B., and Vallyathan V. Effects of pirfenidone on the generation of reactive oxygen species in vitro. J Environ Pathol Toxicol Oncol 18 (1999) 169-177
49. Misra H.P., and Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 204 (2000) 119-126
50. Schreibelt G., van Horssen J., van Rossum S., Dijkstra C.D., Drukarch B., and de Vries H.E. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res Rev 56 (2007) 322-330
51. Tsuchiya H., Kaibori M., Yanagida H., Yokoigawa N., Kwon A.H., Okumura T., et al. Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 40 (2004) 94-101
52. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., and Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 (2003) 2122-2127
53. Aringer M., and Smolen J.S. SLE - complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 5 (2003) 172-177
54. Mageed R.A., and Isenberg D.A. Tumour necrosis factor alpha in systemic lupus erythematosus and anti-DNA autoantibody production. Lupus 11 (2002) 850-855